PL3310333T3 - Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy - Google Patents
Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowyInfo
- Publication number
- PL3310333T3 PL3310333T3 PL16733341T PL16733341T PL3310333T3 PL 3310333 T3 PL3310333 T3 PL 3310333T3 PL 16733341 T PL16733341 T PL 16733341T PL 16733341 T PL16733341 T PL 16733341T PL 3310333 T3 PL3310333 T3 PL 3310333T3
- Authority
- PL
- Poland
- Prior art keywords
- dosage unit
- unit containing
- estetrol component
- orodispersible dosage
- orodispersible
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15172767 | 2015-06-18 | ||
EP16733341.8A EP3310333B1 (en) | 2015-06-18 | 2016-06-17 | Orodispersible dosage unit containing an estetrol component |
PCT/EP2016/064065 WO2016203006A1 (en) | 2015-06-18 | 2016-06-17 | Orodispersible dosage unit containing an estetrol component |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3310333T3 true PL3310333T3 (pl) | 2020-07-13 |
Family
ID=53496426
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL20171407T PL3701944T3 (pl) | 2015-06-18 | 2016-06-17 | Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy |
PL16733341T PL3310333T3 (pl) | 2015-06-18 | 2016-06-17 | Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL20171407T PL3701944T3 (pl) | 2015-06-18 | 2016-06-17 | Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy |
Country Status (41)
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG195121A1 (en) | 2011-06-01 | 2013-12-30 | Estetra S A | Process for the production of estetrol intermediates |
CN107266514A (zh) | 2011-06-01 | 2017-10-20 | 埃斯特拉私人有限责任公司 | 用于产生雌四醇中间体的方法 |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
EP3310333B1 (en) | 2015-06-18 | 2020-04-29 | Estetra SPRL | Orodispersible dosage unit containing an estetrol component |
CN107810001A (zh) | 2015-06-18 | 2018-03-16 | 密特拉制药公司 | 含雌四醇的口腔分散片剂 |
UA123098C2 (uk) | 2015-06-18 | 2021-02-17 | Естетра Спрл | Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент |
MA44206B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
JOP20200260A1 (ar) * | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
JP2023543953A (ja) * | 2020-09-29 | 2023-10-18 | ミリセント・ファーマ・リミテッド | 口腔内分散性配合物 |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
CL2021001762A1 (es) * | 2021-07-01 | 2022-01-21 | Univ Pontificia Catolica Chile | Uso del estetrol como tratamiento para la endometriosis |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3138588A (en) | 1962-08-24 | 1964-06-23 | American Home Prod | 17-ketals of estrone and derivatives thereof |
US3433785A (en) | 1966-07-11 | 1969-03-18 | Sterling Drug Inc | 15,16-disubstituted aromatic steroids,intermediates and processes |
US4826831A (en) | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
CA1306950C (en) | 1987-04-10 | 1992-09-01 | Alec D. Keith | Buccal administration of estrogens |
US5073374A (en) | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
GB2228412B (en) | 1989-02-28 | 1993-04-14 | Syntex Inc | Nicardipine pharmaceutical composition for parenteral administration |
JPH03237557A (ja) | 1990-02-14 | 1991-10-23 | Oki Electric Ind Co Ltd | ニューラルネットワークシミュレータ及び計算機システム |
US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
US5468736A (en) | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
US5895783A (en) | 1993-07-16 | 1999-04-20 | Schering Aktiengesellschaft | Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor |
JPH07101977A (ja) | 1993-10-05 | 1995-04-18 | Kureha Chem Ind Co Ltd | ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤 |
DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
AU2103495A (en) | 1994-08-04 | 1996-03-04 | Biex, Inc. | Method for prediction of premature delivery using estetrol (e4) as an indicator |
WO1997004752A1 (en) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
FR2772272B1 (fr) | 1997-12-16 | 2000-01-14 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation |
AR014133A1 (es) | 1997-12-19 | 2001-02-07 | Smithkline Beecham Corp | Procedimiento para fabricar tabletas de dispersion rapida para administracion oral y una formulacion de dichas tabletas |
US7815937B2 (en) | 1998-10-27 | 2010-10-19 | Biovail Laboratories International Srl | Quick dissolve compositions and tablets based thereon |
US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
US6180682B1 (en) * | 1999-01-26 | 2001-01-30 | Virgil A. Place | Buccal drug delivery system for use in male contraception |
TW548277B (en) | 1999-07-16 | 2003-08-21 | Akzo Nobel Nv | Orally active androgens |
DE60025958T2 (de) | 1999-12-02 | 2006-07-27 | Akzo Nobel N.V. | 14,15-beta-methylen substituierte androgene |
US20020132801A1 (en) | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
SK287719B6 (en) | 2000-01-18 | 2011-07-06 | Bayer Schering Pharma Ag | Drospirenone for hormone replacement therapy |
FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
US8048869B2 (en) | 2001-05-18 | 2011-11-01 | Pantarhei Bioscience B.V. | Pharmaceutical composition for use in hormone replacement therapy |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
ATE449606T1 (de) | 2001-05-23 | 2009-12-15 | Pantarhei Bioscience Bv | Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption |
EP1390042B1 (en) | 2001-05-23 | 2007-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
DK1293210T3 (da) | 2001-05-23 | 2004-03-15 | Pantarhei Bioscience Bv | Midler og fremgangsmåde til hormonal prævention |
US20020193356A1 (en) | 2001-05-23 | 2002-12-19 | Van Beek Agatha Antonia Magdalena | Means and method for hormonal contraception |
CA2448270A1 (en) * | 2001-05-23 | 2002-11-28 | Panterhei Bioscience B.V. | Means and method for hormonal contraception |
WO2003018026A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
WO2003041718A1 (en) | 2001-11-15 | 2003-05-22 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
HU227198B1 (en) | 2001-11-27 | 2010-10-28 | Richter Gedeon Nyrt | Pharmaceutical composition for emergency contraception containing levonorgestrel |
JP5037779B2 (ja) | 2002-02-21 | 2012-10-03 | バイエル ファーマ アクチエンゲゼルシャフト | 1又は複数のステロイド、1又は複数のテトラヒドロ葉酸成分およびビタミンb12を含む医薬組成物 |
US20050147670A1 (en) * | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
CN100352445C (zh) | 2002-06-11 | 2007-12-05 | 潘塔希生物科学股份有限公司 | 一种皮肤护理组合物及其用途 |
CN1691947B (zh) | 2002-06-11 | 2011-11-23 | 潘塔希生物科学股份有限公司 | 雌激素成分在制备用于治疗或预防免疫介导的疾病中的应用以及包含所述雌激素成分的药物组合物 |
SI1526856T1 (sl) | 2002-07-12 | 2008-04-30 | Pantarhei Bioscience Bv | Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka |
DE60309895T2 (de) | 2002-08-28 | 2007-10-18 | Casper, Robert-Frederic, Toronto | Estrogenersatztherapie |
DE60318092T2 (de) | 2002-10-23 | 2008-11-27 | Pantarhei Bioscience B.V. | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung |
DE60330888D1 (de) | 2002-11-05 | 2010-02-25 | Bayer Schering Pharma Ag | Verwendung von drospirenon zur behandlung von hypertension |
EP1562976B1 (en) | 2002-11-08 | 2010-05-26 | Pantarhei Bioscience B.V. | Synthesis of estetrol via estrone derived steroids |
MXPA05011299A (es) | 2003-04-30 | 2006-01-24 | Debiopharm Sa | Metodos y composiciones utilizando la hormona liberadora de la hormona gonadotropina. |
SI1624878T1 (sl) | 2003-05-22 | 2007-02-28 | Pantarhei Bioscience Bv | Uporaba sestavkov, ki obsegajo estrogensko komponento, za zdravljenje in preprecevanje muskuloskeletne bolecine |
WO2005030175A1 (en) | 2003-09-29 | 2005-04-07 | Novo Nordisk Femcare Ag | Hrt formulations |
EP1673071A1 (en) | 2003-09-29 | 2006-06-28 | Novo Nordisk Femcare AG | Improved stability of progestogen formulations |
JP3841804B2 (ja) | 2003-10-15 | 2006-11-08 | 富士化学工業株式会社 | 口腔内速崩壊性錠剤用の組成物 |
EP1535618A1 (en) | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
US20050113350A1 (en) | 2003-11-26 | 2005-05-26 | Bernd Duesterberg | Extended use combination comprising estrogens and progestins |
MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
GB0410616D0 (en) | 2004-05-13 | 2004-06-16 | Unilever Plc | Antiperspirant or deodorant compositions |
PL1755562T3 (pl) | 2004-05-28 | 2014-03-31 | Richter Gedeon Nyrt | Środek antykoncepcyjny zawierający kwas foliowy |
DE102004026670A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
SI1773292T1 (sl) | 2004-07-01 | 2009-10-31 | Lek Pharmaceuticals D.D. | Hitro razgradljiva oralno disperzibilna farmacevtska oblika |
UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
CA2644400C (en) | 2005-02-03 | 2014-04-08 | Nycomed Pharma As | Fast wet-massing method for the preparation of calcium-containing compositions |
JP5004236B2 (ja) | 2005-02-09 | 2012-08-22 | キッセイ薬品工業株式会社 | 口腔内崩壊錠 |
IS7724A (is) | 2005-03-02 | 2006-09-03 | Actavis Group | Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat |
UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
RU2412196C2 (ru) | 2005-05-26 | 2011-02-20 | Зольвай Фармасьютиклз Гмбх | ИНГИБИТОРЫ 17β-ГСД1 И СТС |
KR20080031037A (ko) | 2005-06-29 | 2008-04-07 | 와이어쓰 | 결합형 에스트로겐과 바제독시펜의 제형 |
US20070048369A1 (en) | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
ATE481973T1 (de) | 2006-01-09 | 2010-10-15 | Pantarhei Bioscience Bv | Verfahren zur behandlung einer akuten gefässerkrankung |
US20090221540A1 (en) | 2006-01-09 | 2009-09-03 | Pantarhei Bioscience B.V. | Method of Treating An Acute Vascular Disorder |
WO2007106264A2 (en) | 2006-03-02 | 2007-09-20 | Warner Chilcott Company, Inc. | Extended cycle multiphasic oral contraceptive method |
WO2007146805A2 (en) | 2006-06-08 | 2007-12-21 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty |
US20070286819A1 (en) * | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
US20080113953A1 (en) | 2006-06-08 | 2008-05-15 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
CA2665788A1 (en) | 2006-07-06 | 2008-01-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations |
EP2086550A2 (en) | 2006-11-29 | 2009-08-12 | Wyeth | Estrogen/ serm and estrogen/ progestin bi-layer tablets |
US7867515B2 (en) | 2006-12-20 | 2011-01-11 | TEVA Woman's Health, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
CA2674325A1 (en) | 2007-01-08 | 2008-07-17 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
JP2010515758A (ja) | 2007-01-12 | 2010-05-13 | ワイス エルエルシー | 錠剤中錠剤組成物 |
EP1972618A1 (en) | 2007-03-20 | 2008-09-24 | Nabriva Therapeutics AG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
WO2008156365A1 (en) | 2007-06-21 | 2008-12-24 | Pantarhei Bioscience B.V. | Treatment of meconium aspiration syndrome with estrogens |
EP2170346B1 (en) | 2007-07-19 | 2011-11-16 | Pantarhei Bioscience B.V. | Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation |
FR2920311B1 (fr) | 2007-08-31 | 2010-06-18 | Galenix Innovations | Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation |
JP5399749B2 (ja) | 2008-03-27 | 2014-01-29 | 沢井製薬株式会社 | プロトンポンプ阻害剤を含有する被覆微粒子 |
DE202009018024U1 (de) | 2008-08-01 | 2010-12-09 | Krka Tovarna Zdravil, D.D., Novo Mesto | Quetiapin-Zusammensetzung |
US20110250274A1 (en) | 2008-09-19 | 2011-10-13 | Shaked Ze Ev | Estriol formulations |
CN101780073B (zh) | 2009-01-21 | 2013-07-03 | 重庆圣华曦药业股份有限公司 | 非布司他分散片药物及其制备方法 |
KR101565621B1 (ko) | 2009-01-26 | 2015-11-03 | 신에쓰 가가꾸 고교 가부시끼가이샤 | 저치환도 히드록시프로필셀룰로오스 수분산액을 이용한 습식 조립 타정법 |
DE102009007771B4 (de) | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
EP2410995A1 (en) | 2009-03-26 | 2012-02-01 | Royal College of Surgeons in Ireland | Orodispersible tablets |
ITMI20091109A1 (it) | 2009-06-23 | 2010-12-24 | Wyeth Corp | Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione |
JP5801801B2 (ja) | 2009-06-23 | 2015-10-28 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 緊急避妊のための医薬組成物及び処置方法 |
CN102058604A (zh) | 2009-11-17 | 2011-05-18 | 北京万全阳光医学技术有限公司 | 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法 |
JP5945267B2 (ja) | 2010-04-12 | 2016-07-05 | ユニヴェルシテ クロード ベルナール リヨン 1 | 有機ケイ素ゾルの急速縮合によって得られるハイブリッド材料の製造方法 |
CA2795801C (en) | 2010-04-15 | 2018-05-29 | Bayer Intellectual Property Gmbh | Very low-dosed solid oral dosage forms for hrt |
EP2399904A1 (en) | 2010-05-26 | 2011-12-28 | Nabriva Therapeutics AG | Process for the preparation of pleuromutilins |
AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
WO2012055840A1 (en) | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders |
KR101965002B1 (ko) | 2010-12-02 | 2019-08-13 | 아데어 파마슈티컬스 인코포레이티드 | 급속 분산성 과립, 구강 붕해성 정제 및 방법 |
JP2012240917A (ja) | 2011-05-16 | 2012-12-10 | Zensei Yakuhin Kogyo Kk | 製剤化用微粒子とそれを含む製剤 |
SG195121A1 (en) | 2011-06-01 | 2013-12-30 | Estetra S A | Process for the production of estetrol intermediates |
CN107266514A (zh) | 2011-06-01 | 2017-10-20 | 埃斯特拉私人有限责任公司 | 用于产生雌四醇中间体的方法 |
CL2013003435A1 (es) | 2011-06-01 | 2014-08-01 | Estetra Sprl | Proceso de preparacion de intermediarios de estetrol utilizando catalizadores de paladio y grupos protectores acilantes o sililantes; y uso de dicho proceso para preparar estetrol. |
WO2013012326A1 (en) | 2011-07-19 | 2013-01-24 | Pantarhei Bioscience B.V. | Tablet containing dehydroepiandrosterone (dhea) |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
LT2741824T (lt) | 2011-08-11 | 2017-06-26 | Estetra S.P.R.L. | Estetrolio panaudojimas kaip skubaus kontraceptiko |
NZ620897A (en) | 2011-09-16 | 2016-07-29 | Ferring Bv | A fast dissolving pharmaceutical composition |
SI2764008T1 (sl) | 2011-10-07 | 2016-10-28 | Estetra S.P.R.L. | Postopek za pripravo estetrola |
WO2013090117A1 (en) | 2011-12-13 | 2013-06-20 | Arstat, Inc. | A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen |
EP2653163A1 (en) | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
US9808470B2 (en) | 2012-04-19 | 2017-11-07 | Universite De Liege | Estrogenic components for use in the treatment of neurological disorders |
US9238265B2 (en) | 2012-09-27 | 2016-01-19 | General Electric Company | Backstrike protection during machining of cooling features |
WO2014159377A1 (en) | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
JP6126456B2 (ja) | 2013-05-17 | 2017-05-10 | 東和薬品株式会社 | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 |
US20140341326A1 (en) | 2013-05-20 | 2014-11-20 | Qualcomm Incorporated | Channel estimation with discontinuous pilot signals |
EP3943079A1 (en) | 2013-05-21 | 2022-01-26 | Predictive Therapeutics, LLC | Therapeutic and method of use |
JP6254289B2 (ja) | 2013-09-18 | 2017-12-27 | クリスタル ファルマ、エセ、ア、ウCrystal Pharma,S.A.U. | エステトロールの製造プロセス |
US20150098978A1 (en) | 2013-10-03 | 2015-04-09 | Altria Client Services Inc. | Dissolvable-chewable tablet |
CN105934239A (zh) * | 2013-12-04 | 2016-09-07 | 盖尔德马研究及发展公司 | 优选包含亲脂性活性剂的脂质微胶囊和包含它的组合物,它们的制备方法和它们在皮肤病学和化妆品中的用途 |
DK3079671T3 (en) | 2013-12-12 | 2017-12-11 | Donesta Bioscience B V | Orally disintegrating solid dosage unit containing an estetrol component |
US10571371B2 (en) | 2014-08-07 | 2020-02-25 | Wake Forest University Health Sciences | Compositions and methods for clearing a biological sample |
EP3200802B1 (en) | 2014-09-29 | 2023-07-12 | The Regents of The University of California | Compositions and methods for maintaining cognitive function |
JP2018515552A (ja) | 2015-05-18 | 2018-06-14 | アジル・セラピューティクス・インコーポレイテッドAgile Therapeutics, Inc. | 避妊用組成物ならびに有効性改善および副作用調節方法 |
UA123098C2 (uk) | 2015-06-18 | 2021-02-17 | Естетра Спрл | Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент |
CN107810001A (zh) | 2015-06-18 | 2018-03-16 | 密特拉制药公司 | 含雌四醇的口腔分散片剂 |
EP3310333B1 (en) | 2015-06-18 | 2020-04-29 | Estetra SPRL | Orodispersible dosage unit containing an estetrol component |
MA44206B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
EP3313408B1 (en) | 2015-06-23 | 2023-12-06 | Laboratorios Leon Farma SA | Drospirenone-based contraceptive for a female patient affected with excess weight |
AU2016425935B2 (en) | 2016-10-28 | 2023-01-19 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
US20200046729A1 (en) | 2016-08-05 | 2020-02-13 | Estetra Sprl | Methods using combined oral contraceptive compositions with reduced cardiovascular effects |
SG11202007163WA (en) | 2018-02-07 | 2020-08-28 | Estetra Sprl | Contraceptive composition with reduced cardiovascular effects |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
US10929286B2 (en) | 2018-06-29 | 2021-02-23 | Seagate Technology Llc | Arbitrated management of a shared non-volatile memory resource |
TW202203935A (zh) | 2020-04-16 | 2022-02-01 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
-
2016
- 2016-06-17 EP EP16733341.8A patent/EP3310333B1/en active Active
- 2016-06-17 RS RS20211590A patent/RS62844B1/sr unknown
- 2016-06-17 SI SI201631422T patent/SI3701944T1/sl unknown
- 2016-06-17 SI SI201630752T patent/SI3310333T1/sl unknown
- 2016-06-17 UA UAA201800476A patent/UA123099C2/uk unknown
- 2016-06-17 BR BR112017027229-6A patent/BR112017027229B1/pt active IP Right Grant
- 2016-06-17 MX MX2017016274A patent/MX2017016274A/es unknown
- 2016-06-17 ES ES16733341T patent/ES2800774T3/es active Active
- 2016-06-17 EA EA202090984A patent/EA202090984A1/ru unknown
- 2016-06-17 RS RS20200563A patent/RS60252B1/sr unknown
- 2016-06-17 MD MDE20180407T patent/MD3310333T2/ro unknown
- 2016-06-17 WO PCT/EP2016/064065 patent/WO2016203006A1/en active Application Filing
- 2016-06-17 GE GEAP201614676A patent/GEP20217243B/en unknown
- 2016-06-17 JP JP2017564402A patent/JP6866560B2/ja active Active
- 2016-06-17 MY MYPI2017001863A patent/MY186164A/en unknown
- 2016-06-17 US US15/737,227 patent/US11147771B2/en active Active
- 2016-06-17 PT PT201714078T patent/PT3701944T/pt unknown
- 2016-06-17 LT LTEP16733341.8T patent/LT3310333T/lt unknown
- 2016-06-17 HU HUE20171407A patent/HUE057741T2/hu unknown
- 2016-06-17 PT PT167333418T patent/PT3310333T/pt unknown
- 2016-06-17 HU HUE16733341A patent/HUE049232T2/hu unknown
- 2016-06-17 CN CN202310318485.8A patent/CN116077455A/zh active Pending
- 2016-06-17 EP EP20171407.8A patent/EP3701944B1/en active Active
- 2016-06-17 LT LTEP20171407.8T patent/LT3701944T/lt unknown
- 2016-06-17 PE PE2022002730A patent/PE20231714A1/es unknown
- 2016-06-17 MA MA45972A patent/MA45972B1/fr unknown
- 2016-06-17 DK DK20171407.8T patent/DK3701944T3/da active
- 2016-06-17 CA CA2988495A patent/CA2988495C/en active Active
- 2016-06-17 CU CU2017000161A patent/CU24504B1/es unknown
- 2016-06-17 PE PE2017002732A patent/PE20180522A1/es unknown
- 2016-06-17 NZ NZ737945A patent/NZ737945A/en unknown
- 2016-06-17 ME MEP-2020-96A patent/ME03728B/me unknown
- 2016-06-17 CR CR20180041A patent/CR20180041A/es unknown
- 2016-06-17 DK DK16733341.8T patent/DK3310333T3/da active
- 2016-06-17 TN TNP/2017/000497A patent/TN2017000497A1/en unknown
- 2016-06-17 PL PL20171407T patent/PL3701944T3/pl unknown
- 2016-06-17 KR KR1020237017164A patent/KR20230074847A/ko not_active Application Discontinuation
- 2016-06-17 EA EA201890085A patent/EA035687B1/ru unknown
- 2016-06-17 AU AU2016280858A patent/AU2016280858B2/en not_active Ceased
- 2016-06-17 CN CN201680035626.3A patent/CN107787224A/zh active Pending
- 2016-06-17 PL PL16733341T patent/PL3310333T3/pl unknown
- 2016-06-17 ES ES20171407T patent/ES2906228T3/es active Active
- 2016-06-17 HR HRP20211968TT patent/HRP20211968T1/hr unknown
-
2017
- 2017-12-11 CO CONC2017/0012670A patent/CO2017012670A2/es unknown
- 2017-12-11 DO DO2017000294A patent/DOP2017000294A/es unknown
- 2017-12-12 IL IL256282A patent/IL256282B/en unknown
- 2017-12-14 CL CL2017003209A patent/CL2017003209A1/es unknown
- 2017-12-15 PH PH12017502326A patent/PH12017502326A1/en unknown
- 2017-12-15 SV SV2017005596A patent/SV2017005596A/es unknown
- 2017-12-29 EC ECIEPI201785659A patent/ECSP17085659A/es unknown
-
2018
- 2018-10-24 HK HK18113617.6A patent/HK1254650A1/zh unknown
-
2020
- 2020-05-22 CY CY20201100468T patent/CY1123006T1/el unknown
- 2020-05-26 HR HRP20200850TT patent/HRP20200850T1/hr unknown
-
2021
- 2021-02-16 JP JP2021022465A patent/JP7140355B2/ja active Active
- 2021-05-21 AU AU2021203265A patent/AU2021203265B2/en active Active
- 2021-10-18 US US17/504,087 patent/US11964055B2/en active Active
- 2021-12-22 CY CY20211101127T patent/CY1124878T1/el unknown
-
2022
- 2022-06-06 LT LTPA2022508C patent/LTPA2022508I1/lt unknown
- 2022-06-07 NO NO2022020C patent/NO2022020I1/no unknown
- 2022-06-07 HU HUS2200027C patent/HUS2200027I1/hu unknown
- 2022-12-05 AU AU2022283615A patent/AU2022283615B2/en active Active
-
2023
- 2023-05-12 US US18/196,617 patent/US11793760B2/en active Active
-
2024
- 2024-02-23 AU AU2024201228A patent/AU2024201228A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2200027I1 (hu) | Esztetrol komponenst tartalmazó, szájban diszpergálódó adagolási egység | |
HK1251940A1 (zh) | 含雌四醇組分的口腔分散劑量單位 | |
HK1254649A1 (zh) | 含雌四醇的口腔分散片劑 | |
HUE054589T2 (hu) | Szájban diszpergálódó esztetrol tartalmú tabletta | |
HK1258970A1 (zh) | 醫用輸送裝置 | |
GB201506788D0 (en) | Medicament delivery device | |
GB2537639B (en) | Medicament delivery device | |
GB201506780D0 (en) | Improved medicament delivery device | |
GB201506781D0 (en) | Improved medicament delivery device |